The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?
作者信息
Ricci Angela Dalia, Rizzo Alessandro, Brandi Giovanni
机构信息
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.
出版信息
ESMO Open. 2020 Sep;5(5):e001042. doi: 10.1136/esmoopen-2020-001042.
Abstract
摘要
相似文献
1
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?胆管癌（BTC）中的DNA损伤修复（DDR）途径：一个新的潘多拉魔盒？
ESMO Open. 2020 Sep;5(5):e001042. doi: 10.1136/esmoopen-2020-001042.
2
Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.胆道癌与同源重组缺陷中的基因组改变：利用PARP抑制剂的合成致死性
Chin Clin Oncol. 2020 Feb;9(1):6. doi: 10.21037/cco.2020.02.02. Epub 2020 Feb 20.
3
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.ET-743在人胆道癌临床前模型中的抗癌作用及基因调控
BMC Cancer. 2014 Dec 5;14:918. doi: 10.1186/1471-2407-14-918.
4
Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations.胆道癌：流行病学、分子发病机制及遗传风险关联
Chin Clin Oncol. 2016 Oct;5(5):61. doi: 10.21037/cco.2016.10.09.
5
Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer.胆汁酸加速胆管癌中erbB2诱导的促肿瘤活性。
Mol Carcinog. 2015 Jun;54(6):459-72. doi: 10.1002/mc.22118. Epub 2013 Dec 3.
6
K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.K-Ras 突变和扩增状态可预测耐药性，基底 pAKT 水平高可预测对依维莫司在胆管癌细胞系中的敏感性。
Mol Oncol. 2017 Sep;11(9):1130-1142. doi: 10.1002/1878-0261.12078. Epub 2017 Jun 14.
7
Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer.氧化应激相关基因的变异通过 Nrf2 介导的信号通路影响胆道癌的化疗敏感性。
EBioMedicine. 2019 Oct;48:143-160. doi: 10.1016/j.ebiom.2019.08.037. Epub 2019 Oct 4.
8
The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.组蛋白甲基转移酶 G9a：胆管癌治疗的新靶点。
Hum Pathol. 2018 Feb;72:117-126. doi: 10.1016/j.humpath.2017.11.003. Epub 2017 Nov 11.
9
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?聚（ADP-核糖）聚合酶抑制剂在胆管癌中的应用：初来乍到者？
Medicines (Basel). 2020 Aug 31;7(9):54. doi: 10.3390/medicines7090054.
10
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.使用游离DNA检测转移性胆管癌中的PIK3CA突变
Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432.
引用本文的文献
1
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.多组学分析揭示了晚期不可切除胆管癌化学免疫治疗疗效和预后的预测生物标志物。
BMC Med. 2025 Jul 22;23(1):435. doi: 10.1186/s12916-025-04263-z.
2
Comparative efficacy of targeted therapy, chemotherapy and their combination for advanced cholangiocarcinoma: a systematic review and network meta-analysis.靶向治疗、化疗及其联合治疗晚期胆管癌的疗效比较：一项系统评价和网状Meta分析
PeerJ. 2025 May 14;13:e19386. doi: 10.7717/peerj.19386. eCollection 2025.
3
Preoperative glasgow prognostic score was an effective prognostic indicator in patients with biliary tract cancer.术前格拉斯哥预后评分是胆道癌患者有效的预后指标。
Front Immunol. 2025 Apr 8;16:1560944. doi: 10.3389/fimmu.2025.1560944. eCollection 2025.
4
Comparison of monotherapy and combination therapy for older patients with advanced biliary tract cancer: a retrospective study.老年晚期胆管癌患者单药治疗与联合治疗的比较：一项回顾性研究。
BMC Cancer. 2025 Apr 9;25(1):653. doi: 10.1186/s12885-025-14014-1.
5
Identifying a unique chromosomal pattern to predict the gemcitabine response in patients with cholangiocarcinoma.识别一种独特的染色体模式以预测胆管癌患者对吉西他滨的反应。
Sci Rep. 2025 Apr 8;15(1):11984. doi: 10.1038/s41598-025-96442-4.
6
Role of cancer stem cell heterogeneity in intrahepatic cholangiocarcinoma.癌症干细胞异质性在肝内胆管癌中的作用
Transl Cancer Res. 2025 Feb 28;14(2):1265-1281. doi: 10.21037/tcr-24-1286. Epub 2025 Feb 26.
7
Novel Insights into PGM2L1 as a Prognostic Biomarker in Cholangiocarcinoma: Implications for Metabolic Reprogramming and Tumor Microenvironment Modulation.PGM2L1作为胆管癌预后生物标志物的新见解：对代谢重编程和肿瘤微环境调节的意义
Int J Med Sci. 2025 Feb 11;22(5):1158-1166. doi: 10.7150/ijms.106566. eCollection 2025.
8
Sex-related disparities in outcomes of survival in biliary tract cancer patients.胆管癌患者生存结局的性别差异
J Cancer Res Clin Oncol. 2025 Feb 27;151(2):95. doi: 10.1007/s00432-025-06096-y.
9
Comparing Immunotherapy Versus Chemotherapy Alone as Second-Line Therapy for Malignant Tumors of the Biliary Tract: A Retrospective Study.比较免疫疗法与单纯化疗作为胆道恶性肿瘤二线治疗的疗效：一项回顾性研究。
Clin Med Insights Oncol. 2025 Feb 16;19:11795549251317012. doi: 10.1177/11795549251317012. eCollection 2025.
10
PPIH is a novel diagnostic biomarker associated with immune infiltration in cholangiocarcinoma.PPIH是一种与胆管癌免疫浸润相关的新型诊断生物标志物。
BMC Cancer. 2025 Feb 7;25(1):218. doi: 10.1186/s12885-025-13607-0.
本文引用的文献
1
Molecular profile of BRCA-mutated biliary tract cancers.BRCA 突变型胆道癌的分子特征。
ESMO Open. 2020 Jun;5(3):e000682. doi: 10.1136/esmoopen-2020-000682.
2
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.基因组方法鉴定胰腺导管腺癌同源重组缺陷并优化治疗选择。
Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. doi: 10.1158/1078-0432.CCR-20-0418. Epub 2020 May 22.
3
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.纳武利尤单抗治疗晚期难治性胆道癌患者的 2 期多中心研究。
JAMA Oncol. 2020 Jun 1;6(6):888-894. doi: 10.1001/jamaoncol.2020.0930.
4
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.HLA 校正的肿瘤突变负担和同源重组缺陷预测晚期非小细胞肺癌患者对 PD-(L)1 阻断的反应。
Ann Oncol. 2020 Jul;31(7):902-911. doi: 10.1016/j.annonc.2020.04.004. Epub 2020 Apr 19.
5
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.多种癌症类型中同源重组相关基因突变的患病率。
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00286. Epub 2018 Jul 23.
Zotero 插件